{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:10:48Z","timestamp":1791205848421,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T00:00:00Z","timestamp":1463529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Allergy Immunology"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Targeting the IgE pathway is a clinically validated strategy for treating IgE\u2010mediated diseases. Omalizumab, an anti\u2010IgE antibody, which binds to free IgE and prevents the binding of IgE to Fc\u03b5RI on mast cells and basophils has been approved for severe persistent allergic asthma and chronic spontaneous (idiopathic) urticaria. The therapeutic efficacy of anti\u2010IgE has also been reported in allergic rhinitis, allergic bronchopulmonary aspergillosis, latex allergy, atopic dermatitis, allergic urticaria, anaphylaxis, and others. Anti\u2010C\u03b5mX, which binds to membrane\u2010bound IgE (mIgE) on IgE\u2010switched B cells, lyses mIgE\u2010expressing B lymphoblasts and prevents the allergen\u2010induced generation of IgE\u2010producing plasma cells, offers an alternative mechanism of intervening with the IgE inflammatory pathway. Because anti\u2010C\u03b5mX does not bind to free IgE, it can modulate the IgE pathway regardless of the serum IgE levels in treated patients. These unique pharmacologic mechanisms potentially enable anti\u2010C\u03b5mX to provide different clinical utilities from anti\u2010IgE and serve as a therapeutic and a prophylactic in some IgE\u2010mediated diseases, which are not adequately treated with current medicine.<\/jats:p>","DOI":"10.1111\/pai.12584","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T07:56:40Z","timestamp":1461052600000},"page":"446-451","source":"Crossref","is-referenced-by-count":25,"title":["Treating IgE\u2010mediated diseases via targeting IgE\u2010expressing B cells using an anti\u2010C\u03b5mX antibody"],"prefix":"10.1111","volume":"27","author":[{"given":"Sean S.","family":"Liour","sequence":"first","affiliation":[{"name":"Fountain Biopharma, Inc. Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Tom","sequence":"additional","affiliation":[{"name":"Genomics Research Center Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueh\u2010Hsuan","family":"Chan","sequence":"additional","affiliation":[{"name":"Fountain Biopharma, Inc. Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tse Wen","family":"Chang","sequence":"additional","affiliation":[{"name":"Genomics Research Center Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,5,18]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/2049-6958-10-1"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3792"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.04.036"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S40244"},{"key":"e_1_2_9_6_1","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.4049\/jimmunol.99.6.1187","article-title":"Identification of gamma\u2010E\u2010antibodies as a carrier of reaginic activity","volume":"99","author":"Ishizaka K","year":"1967","journal-title":"J Immunol"},{"key":"e_1_2_9_7_1","first-page":"381","article-title":"Immunological studies of an atypical (myeloma) immunoglobulin","volume":"13","author":"Johansson SG","year":"1967","journal-title":"Immunology"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3632"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012204"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2755"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/72601"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(06)93002-8"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S49409"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12400"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.28394"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22216"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.11.029"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.782391"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/1939-4551-7-17"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2009.03.008"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.5114\/pdia.2014.40657"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.5114\/pdia.2014.40553"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0902437"},{"key":"e_1_2_9_24_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4049\/jimmunol.148.1.129","article-title":"A new isoform of human membrane\u2010bound IgE","volume":"148","author":"Peng C","year":"1992","journal-title":"J Immunol"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI40141"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2012.06.004"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008961"},{"key":"e_1_2_9_28_1","first-page":"A5168","article-title":"Efficacy And Safety Of Quilizumab In Adults With Allergic Asthma Inadequately Controlled On Inhaled Corticosteroids And A Second Controller (COSTA Study)","volume":"191","author":"Harris JM","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-011-8252-4"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsi.2012.10.001"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.23.2956"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200908-086AL"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.49.10.1002"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2014.12.008"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar4069"}],"container-title":["Pediatric Allergy and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpai.12584","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pai.12584","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T07:25:45Z","timestamp":1695540345000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pai.12584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,18]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1111\/pai.12584"],"URL":"https:\/\/doi.org\/10.1111\/pai.12584","archive":["Portico"],"relation":{},"ISSN":["0905-6157","1399-3038"],"issn-type":[{"value":"0905-6157","type":"print"},{"value":"1399-3038","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,18]]}}}